An nNOS/PSD-95 interaction inhibitor
ZL006 is an inhibitor of the protein-protein interaction between neuronal nitric oxide synthase (nNOS) and postsynaptic density protein-95 (PSD-95).1 It inhibits NMDA-induced lactate dehydrogenase release (IC50 = 0.082 ?M), as well as glutamate and glycine-induced, NMDA receptor-dependent production of nitric oxide (NO), in primary mouse neurons. ZL006 (1.5 mg/kg) prevents ischemia-induced increases in nNOS-PSD-95 complex formation in cortices isolated from a mouse model of ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO). It reduces infarct size and increases survival in the same model. ZL006 suppresses mechanical and cold allodynia in a mouse model of neuropathic pain induced by paclitaxel .2
1.Zhou, L., Li, F., Xu, H.-B., et al.Treatment of cerebral ischemia by disrupting ischemia-induced interaction of nNOS with PSD-95Nat. Med.16(12)1439-1443(2010) 2.Lee, W.-H., Xu, Z., Ashpole, N.M., et al.Small molecule inhibitors of PSD95-nNOS protein-protein interactions as novel analgesicsNeuropharmacology97464-475(2015)
|
Cell experiment: |
BCECs are seeded in 96-well plates in 200 μL of DMEM medium to obtain a concentration of 2000 cells per well, and incubated for 24 h. The medium in each well is then incubated for 72 h with 200 μL medium containing blank vehicle, P-LPs/ZL006, T7-P-LPs/ZL006 and ZL006 (free drug dissolved in DMSO) with a series of concentrations ranging from 0.001 to 100 μg/mL. The MTT absorbance at 570 nm of each well is measured by a microplate reader. |
|
Animal experiment: |
ICR mice weighting 20 ± 2 g are divided into three groups at random (n=12). Free ZL006, P-LPs/ZL006 and T7-P-LPs/ZL006 (all containing ZL006 4 mg/kg) are administered to each group through intravenous route, respectively. At designated time intervals (0.5, 1 and 2 h), the mice are executed and the major organs samples including brain, heart, liver, spleen, lung and kidney are collected. Before pretreatment, these tissues are rinsed with cold saline solution to remove the blood and then blotted with paper towel. Protein precipitation of the samples is performed before analysis. Then the samples are injected into the LC-MS/MS systems for analysis. The LC-MS/MS system consists of an Agilent Series 1200 HPLC system and a 6410 Triple Quad LC/MS mass spectrometer. The data is collected and processed using the Agilent MassHunter Workstation Software. |
|
参考文献: [1]. Wang Z, et al. Enhanced anti-ischemic stroke of ZL006 by T7-conjugated PEGylated liposomes drug delivery system. Sci Rep. 2015 Jul 29;5:12651. |
|
动态评分
0.0